JP2022521797A5 - - Google Patents
Info
- Publication number
- JP2022521797A5 JP2022521797A5 JP2021550133A JP2021550133A JP2022521797A5 JP 2022521797 A5 JP2022521797 A5 JP 2022521797A5 JP 2021550133 A JP2021550133 A JP 2021550133A JP 2021550133 A JP2021550133 A JP 2021550133A JP 2022521797 A5 JP2022521797 A5 JP 2022521797A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- independently selected
- pharmaceutically acceptable
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962811432P | 2019-02-27 | 2019-02-27 | |
| US62/811,432 | 2019-02-27 | ||
| US201962819204P | 2019-03-15 | 2019-03-15 | |
| US62/819,204 | 2019-03-15 | ||
| US201962825667P | 2019-03-28 | 2019-03-28 | |
| US62/825,667 | 2019-03-28 | ||
| US201962840254P | 2019-04-29 | 2019-04-29 | |
| US62/840,254 | 2019-04-29 | ||
| US201962871694P | 2019-07-08 | 2019-07-08 | |
| US62/871,694 | 2019-07-08 | ||
| US201962885055P | 2019-08-09 | 2019-08-09 | |
| US62/885,055 | 2019-08-09 | ||
| US201962901142P | 2019-09-16 | 2019-09-16 | |
| US62/901,142 | 2019-09-16 | ||
| US201962931043P | 2019-11-05 | 2019-11-05 | |
| US62/931,043 | 2019-11-05 | ||
| US202062975088P | 2020-02-11 | 2020-02-11 | |
| US62/975,088 | 2020-02-11 | ||
| PCT/US2020/019944 WO2020176654A1 (en) | 2019-02-27 | 2020-02-26 | Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022521797A JP2022521797A (ja) | 2022-04-12 |
| JP2022521797A5 true JP2022521797A5 (enExample) | 2023-02-17 |
| JP7709379B2 JP7709379B2 (ja) | 2025-07-16 |
Family
ID=72238693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021550133A Active JP7709379B2 (ja) | 2019-02-27 | 2020-02-26 | イミプリドン様薬剤に対する薬物反応のバイオマーカとしてのカゼイン分解プロテアーゼｐの機能の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12459945B2 (enExample) |
| EP (1) | EP3930714A4 (enExample) |
| JP (1) | JP7709379B2 (enExample) |
| CN (2) | CN113795251B (enExample) |
| AU (2) | AU2020228047B2 (enExample) |
| CA (1) | CA3131740A1 (enExample) |
| WO (1) | WO2020176654A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230339947A1 (en) * | 2019-02-27 | 2023-10-26 | Madera Therapeutics, LLC | Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents |
| CN117580578A (zh) * | 2021-05-13 | 2024-02-20 | 奇默里克斯公司 | 用于复发性原发性cns肿瘤的方法及用途 |
| CN115611896A (zh) * | 2021-07-16 | 2023-01-17 | 中国药科大学 | 含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法与制药用途 |
| CN119997956A (zh) * | 2022-08-05 | 2025-05-13 | 奇默里克斯公司 | 药物组合物及其用于治疗胶质瘤的用途 |
| CN118724903A (zh) * | 2023-03-31 | 2024-10-01 | 苏州安赛隆医药科技有限公司 | 并环结构化合物、其制备方法及其用途以及药物组合物及其用途 |
| CN119039287A (zh) * | 2023-05-29 | 2024-11-29 | 中国药科大学 | 一类四氢吡啶并嘧啶酮衍生物及其制备方法与应用 |
| EP4488279A1 (en) * | 2023-07-03 | 2025-01-08 | Centro Atlantico del Medicamento S.A (Ceamed, S.A) | Substituted hexahydro-2h-pyrazino[1,2-a]pyrazin-1(6h)-one derivatives as activators of human caseinolytic protease p (hsclpp) |
| CN121816351A (zh) * | 2023-07-10 | 2026-04-07 | 苏州安赛隆医药科技有限公司 | 人源酪蛋白水解蛋白酶p激动剂及其用途 |
| CN119306718A (zh) * | 2023-07-11 | 2025-01-14 | 中科中山药物创新研究院 | 一种咪唑并吡啶并嘧啶酮类化合物及其制备方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| JP2775346B2 (ja) | 1992-04-03 | 1998-07-16 | アプライド バイオシステムズ，インコーポレイテッド | プローブ構成物および方法 |
| US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
| ES2134284T3 (es) | 1993-04-23 | 1999-10-01 | Hoechst Ag | Pirido-pirimidindionas, procedimiento para su preparacion y su empleo como medicamentos. |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
| GB9401833D0 (en) | 1994-02-01 | 1994-03-30 | Isis Innovation | Method for discovering ligands |
| WO1997027317A1 (en) | 1996-01-23 | 1997-07-31 | Affymetrix, Inc. | Nucleic acid analysis techniques |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
| WO2008130584A1 (en) * | 2007-04-20 | 2008-10-30 | Schering Corporation | Pyrimidinone derivatives and methods of use thereof |
| AU2010216633A1 (en) * | 2009-02-23 | 2011-09-08 | Msd K.K. | Pyrimidin-4(3H)-one derivatives |
| WO2012079164A1 (en) | 2010-12-16 | 2012-06-21 | The Governing Council Of The University Of Toronto | Activators of cylindrical proteases |
| HUE069651T2 (hu) | 2014-03-31 | 2025-03-28 | Scripps Research Inst | Farmakofór TRAIL indukcióra |
| CN104860948B (zh) | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | 咪唑并嘧啶酮类化合物及其制备方法和应用 |
| US11091483B2 (en) | 2016-08-12 | 2021-08-17 | Madera Therapeutics, LLC | Protein kinase regulators |
| EP3496720A4 (en) | 2016-08-12 | 2020-06-10 | Nanjing Gator Meditech Company, Ltd. | PROTEIN KINASE REGULATORS |
| WO2020172485A1 (en) * | 2019-02-22 | 2020-08-27 | Board Of Regents, The University Of Texas System | Methods of using imipridones |
| US20230339947A1 (en) * | 2019-02-27 | 2023-10-26 | Madera Therapeutics, LLC | Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents |
-
2020
- 2020-02-26 AU AU2020228047A patent/AU2020228047B2/en active Active
- 2020-02-26 CA CA3131740A patent/CA3131740A1/en active Pending
- 2020-02-26 CN CN202080031455.3A patent/CN113795251B/zh active Active
- 2020-02-26 EP EP20762147.5A patent/EP3930714A4/en active Pending
- 2020-02-26 WO PCT/US2020/019944 patent/WO2020176654A1/en not_active Ceased
- 2020-02-26 CN CN202511975073.7A patent/CN121758447A/zh active Pending
- 2020-02-26 JP JP2021550133A patent/JP7709379B2/ja active Active
-
2021
- 2021-08-27 US US17/459,960 patent/US12459945B2/en active Active
-
2026
- 2026-02-13 AU AU2026201069A patent/AU2026201069A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024105360A5 (enExample) | ||
| JP2024520481A5 (enExample) | ||
| CA2324418A1 (en) | Novel opiate compounds, methods of making and methods of use | |
| RU2013156074A (ru) | Диазакарбазолы и способы применения | |
| CA2463569A1 (en) | Activator for peroxisome proliferator-activated receptor .delta. | |
| JP2003519676A5 (enExample) | ||
| AR067896A1 (es) | Procedimiento para sintetizar compuestos utiles para tratar hepatitis c | |
| JP2024522174A5 (enExample) | ||
| JP2023504542A5 (enExample) | ||
| JP2017137291A5 (enExample) | ||
| AR046791A1 (es) | Tiadiazoles como ligandos del receptor cxc y cc-quimioquina; composiciones farmaceuticas que los contienen como principio activo y su empleo en la preparacion de medicamentos. | |
| CA2578068A1 (en) | S-triazolyl .alpha.-mercaptoacetanildes as inhibitors of hiv reverse transcriptase | |
| RU2017126261A (ru) | Аэолиновые соединения, замещенные конденсированной кольцевой системой | |
| JP2005514398A5 (enExample) | ||
| RU2015106915A (ru) | МОДУЛЯТОРЫ α7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И ИХ ПРИМЕНЕНИЕ | |
| AR083565A1 (es) | Compuestos heterociclicos utiles para tratar infecciones por vhc en humanos y composiciones farmaceuticas que los contienen | |
| JP2015524457A5 (enExample) | ||
| JP2015536947A5 (enExample) | ||
| JP2024517692A5 (enExample) | ||
| JP2003525286A5 (enExample) | ||
| JP2020531531A5 (enExample) | ||
| JP2023537274A5 (enExample) | ||
| JP2023537271A5 (enExample) | ||
| JP2022533939A5 (enExample) | ||
| JP2023532128A5 (enExample) |